Articles related to ERECTILE DYSFUNCTION (ED)

Research examining cannabis and sexual function suggests possible associations with increased sexual frequency and orgasm satisfaction in some users, but findings remain inconsistent, largely observational, and influenced by dose, timing, formulation, and individual factors.

Online claims linking GLP-1 receptor agonists to increased penis size continue attracting patient attention. Available evidence suggests perceived changes may reflect weight loss and erectile function changes rather than anatomic growth.

A two-sample analysis of GWAS data identified genetically predicted associations between six commonly prescribed medications and increased erectile dysfunction risk, while aspirin did not reach statistical significance after SNP exclusions.

Neoadjuvant apalutamide plus abiraterone and ADT before radical prostatectomy was associated with improved 12-month potency recovery and lower positive surgical margin rates compared with surgery alone in a small phase 2 trial of men with high-risk localized prostate cancer.

Topical finasteride absorption through skin into bloodstream produces adverse events consistent with approved oral finasteride products, with 32 documented cases including erectile dysfunction, anxiety, and cognitive symptoms reported between 2019-2024.

Recent studies show cannabis use before intercourse helped 67% of women with orgasmic dysfunction achieve improved sexual satisfaction, highlighting its potential as a therapeutic option for female sexual health.